Treatment of myeloma bone disease with proteasomal and NF-&kgr;B activity inhibitors
US6492333B1 · kind B1 · utility
49Cited by
1References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 9, 1999 |
| Grant date | Dec 10, 2002 |
| Priority date | — |
| Expiry date | Apr 9, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-&kgr;B. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-&kgr;B provides a useful means to identify agents to treat myeloma bone disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.